JAMA Neurology publishes Phase 3 study results on the efficacy and safety of FINTEPLA®▼(fenfluramine) oral solution for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) Primary endpoint was met demonstrating that fenfluramine, as adjunctive treatment, is effective in significantly reducing the frequency of drop seizures in LGS patients compared to placebo1 LGS is a…
NMOSD trial success
ULTOMIRIS® (ravulizumab-cwvz) Met Primary Endpoint in CHAMPION-NMOSD (Neuromyelitis Optica Spectrum Disorder) Phase III Trial Positive high-level results from the open-label Phase III CHAMPION-NMOSD trial showed that ULTOMIRIS®(ravulizumab-cwvz) achieved a statistically significant and clinically meaningful reduction in the risk of relapse in adults with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD) compared to the external placebo…
New Three-Year Data for Genentech’s Evrysdi (risdiplam)
Long-term improvements in survival and motor milestones in babies with Type 1 Spinal Muscular Atrophy (SMA) – 91% of infants treated with Evrysdi in the FIREFISH study were still alive at three years – – Infants treated with Evrysdi maintained or continued to improve in measures of motor function, including their ability to sit without…
Keto diet improved life quality of RRMS patients in trial
Eating a ketogenic diet — one low in carbohydrates and high in fats — led to less fatigue and depression for people with relapsing-remitting multiple sclerosis (RRMS) in a small clinical trial that was designed to assess the tolerability of the dietary intervention. Measures of disability and quality of life also improved during the study while participants…
NfL test for multiple sclerosis
Quanterix Granted Breakthrough Device Designation from U.S. FDA Blood-based assay has the potential to serve the multiple sclerosis (MS) community in management of relapsing-remitting form of the disease April 22, 2022 08:30 AM Eastern Daylight Time: Quanterix Corporation, a company digitising biomarker analysis with the goal of advancing the science of precision health, announced that…
Using telemedicine in neuro-oncology – practical guidance
The COVID-19 pandemic has ensured the expansion of telemedicine into nearly every medical specialty. This article summarises current practice and makes recommendations for integrating virtual care in the practice of neuro-oncology. It identifies current telemedicine practice, provides practical guidance for conducting telemedicine visits, and generates recommendations for integrating virtual care into neuro-oncology practice. Practical aspects…
Study links gut microbiota strains with more severe strokes and poorer post-stroke recovery
A new study has identified strains of gut microbiota that are associated with more severe strokes and worse post-stroke recovery, revealing that the gut microbiome could be an important factor in stroke risk and outcomes1. The study, presented 28 April 2022 at the European Stroke Organisation Conference (ESOC 2022) pinpointed specific groups of bacteria associated…
Pregabalin may slightly increase risk of major congenital malformations
20 April 2022: The Medicines and Healthcare products Regulatory Agency (MHRA) has issued a drug safety update on the use of pregabalin in pregnancy, after a new study suggests that it may slightly increase the risk of major congenital malformations. Advice for healthcare professionals is that potentially fertile women should continue to use effective contraception…
EC marketing authorisation for Vydura for migraine
Pfizer Inc and Biohaven Pharmaceutical Holding Company Ltd announced on 27th April that the European Commission (EC) has granted marketing authorisation for VYDURA® (rimegepant), a calcitonin gene-related peptide (CGRP) receptor antagonist for both the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine in adults who have at least four migraine attacks…
